1048973-47-2 Usage
Uses
Used in Pharmaceutical Industry:
MDA 19 is used as a therapeutic agent for the treatment of neuropathic pain. Its agonistic action on the CB2 receptor has been shown to effectively attenuate tactile allodynia in neuropathic rats, suggesting its potential for alleviating neuropathic pain without producing adverse effects in the central nervous system.
Used in Research Applications:
In addition to its potential therapeutic use, MDA 19 is also utilized as a research tool for studying the role of the CB2 receptor in various physiological and pathological processes. Its selectivity for the CB2 receptor makes it a valuable compound for investigating the specific functions and mechanisms of this receptor in different experimental models.
Used in Synthetic Cannabinoid Development:
MDA 19 is an important compound in the development of synthetic cannabinoids, which are designed to mimic the effects of naturally occurring cannabinoids found in the cannabis plant. Its unique properties and selectivity for the CB2 receptor make it a promising candidate for the development of novel therapeutic agents with fewer side effects and improved safety profiles compared to traditional cannabinoids.
Check Digit Verification of cas no
The CAS Registry Mumber 1048973-47-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,4,8,9,7 and 3 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 1048973-47:
(9*1)+(8*0)+(7*4)+(6*8)+(5*9)+(4*7)+(3*3)+(2*4)+(1*7)=182
182 % 10 = 2
So 1048973-47-2 is a valid CAS Registry Number.
1048973-47-2Relevant academic research and scientific papers
HYDRAZONE MODULATORS OF CANNABINOID RECEPTORS
-
Page/Page column 55-56, (2009/03/07)
Hydrazone compounds which modulate cannabinoid receptors are presented. Pharmaceutical compositions containing these compounds, methods of using these compounds as modulators of cannabinoid receptors and processes for synthesizing these compounds are also described herein.
Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain
Diaz, Philippe,Xu, Jijun,Astruc-Diaz, Fanny,Pan, Hao-Min,Brown, David L.,Naguib, Mohamed
experimental part, p. 4932 - 4947 (2009/07/11)
There is growing interest in using cannabinoid receptor 2 (CB2) agonists for the treatment of neuropathic pain. We have synthesized a novel series of N-alkyl isatin acylhydrazone derivatives and have identified and characterized several of them as novel analogues with high functional activity and selectivity at human CB2 receptors using [35S]GTP-γ-S assays. Binding affinities at human CB2 and CB1 were determined for compounds 28, 33, 40, 48, and 58. Structure-activity relationship studies of this novel series led to optimization of our lead compound, compound 33 (MDA19). Compound 33 possessed potent antiallodynic effects in a rat model of neuropathic pain but did not affect rat locomotor activity. More potent and more CB2-receptor-selective compounds, including compounds 37, 40, and 48, were also discovered.
